[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
GILEAD WORLD MARKETS, LTD.-PHARMACHEM TECHNOLOGIES
(GRAND BAHAMA), LTD.
TENOFOVIR DISOPROXIL FUMARATE MANUFACTURING SUPPLY AGREEMENT
T HE P ARTIES HEREBY ACKNOWLEDGE AND AGREE THE FOLLOWING :
THIS SUPPLY AGREEMENT ( “Agreement” ) is entered into as of July 17, 2003, by and between PharmaChem
Technologies (Grand Bahama), Ltd., a Commonwealth of the Bahamas company ( “PharmaChem” ) having its principal
place of business at [ * ] Freeport, Grand Bahama, Commonwealth of The Bahamas, , and Gilead World Markets, Ltd., a
company operating under the laws of the Cayman Islands ( “GWM” ) having its principal place of business at Queensgate
House, South Church Street, PO Box 1234GT, Grand Cayman. PharmaChem and GWM may be referred to individually as a
“Party” and collectively as the “Parties” in this Agreement.
WHEREAS, PharmaChem is a known manufacturer of active pharmaceutical ingredients with expertise in cGMP
manufacturing, and GWM and its designees manufacture and market pharmaceutical products for human use, including
tenofovir disoproxil fumarate 300 mg known as Viread ® ( “Finished Product” );
WHEREAS, PharmaChem and GWM desire to establish mutually agreeable terms for the commercial supply of bulk
tenofovir disoproxil fumarate ( “Product” ) as an active pharmaceutical ingredient by PharmaChem to GWM.
WHEREAS, the Parties’ obligations under this Agreement are subject to the condition precedent of the Closing of the
acquisition by PharmaChem [ * ] of the plant located in [ * ] Freeport, Grand Bahama, (the “ Plant ”) within and not later
than August 31 st , 2003 (the business day immediately after the date of Closing of the acquisition of the Plant is hereinafter
defined as the “ Effective Date ”).